
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the potential to cure autoimmune and inflammatory …